To the Editor:Lymphomas,classified as hematological malignancies(HMs),[1,2]continue to pose significant challenges to public health.Although gut microbiota is widely connected with lymphoma via several plausible mecha...To the Editor:Lymphomas,classified as hematological malignancies(HMs),[1,2]continue to pose significant challenges to public health.Although gut microbiota is widely connected with lymphoma via several plausible mechanisms,[1–4]the causality and directionality of this relationship are not fully understood.Therefore,a bidirectional multivariable Mendelian randomization(MR)study design was adopted to establish a robust causal relationship between gut microbiota and the development of lymphomas.展开更多
Objective To explore the survival benefits of the concept of staged treatment of Chinese medicine(STCM)combined with chemotherapy in patients with metastatic colorectal cancer(mCRC).Methods Using a bidirectional cohor...Objective To explore the survival benefits of the concept of staged treatment of Chinese medicine(STCM)combined with chemotherapy in patients with metastatic colorectal cancer(mCRC).Methods Using a bidirectional cohort study method,patients with mCRC who received chemotherapy and"continuously received≥3 months of ST-CM"were considered as the exposure factor.Patients who meet this exposure factor were included in the integrative medicine cohort(Group A),receiving conventional treatment combined with ST-CM;those who do not meet this exposure factor were included in the Western medicine cohort(Group B),receiving conventional treatment.The overall survival(OS)and survival rates from the lst,2nd,and 3rd year were compared between the two groups.Results A total of 519 patients were recruited in this study.The median overall survival(mOS)for cohort A(324 cases)and cohort B(195 cases)were 34.3 months and 21.3 months,respectively(HR 0.65,95%CI:0.535-0.793,P<0.001).The survival rates at 1 st,2nd and 3rd years for Group A and Group B were 95.6%and 83.2%,38.6%and 24.7%,21.6%and 12.4%,respectively,with group A showing better outcomes than group B(P<0.001).Subgroup analysis revealed that regardless of gender,primary tumor site,genetic type,combination with targeted therapy,presence of liver metastasis,and absence of peritoneal metastasis,Group A's mOS was significantly better than Group B,with all differences being statistically significant(P<0.05).Conclusion ST-CM combined with chemotherapy can prolong the OS of mCRC patients,and improve the survival rates from the 1st,2nd and 3rd year.展开更多
基金This work was supported by grants from the National Natural Science Foundation of China(No.82020108004)Chongqing Young and Middle-aged Medical High-end Talent Project(No.YXGD202467)Natural Science Foundation of Chongqing(No.CSTB2022NSCQ-MSX084).
文摘To the Editor:Lymphomas,classified as hematological malignancies(HMs),[1,2]continue to pose significant challenges to public health.Although gut microbiota is widely connected with lymphoma via several plausible mechanisms,[1–4]the causality and directionality of this relationship are not fully understood.Therefore,a bidirectional multivariable Mendelian randomization(MR)study design was adopted to establish a robust causal relationship between gut microbiota and the development of lymphomas.
文摘Objective To explore the survival benefits of the concept of staged treatment of Chinese medicine(STCM)combined with chemotherapy in patients with metastatic colorectal cancer(mCRC).Methods Using a bidirectional cohort study method,patients with mCRC who received chemotherapy and"continuously received≥3 months of ST-CM"were considered as the exposure factor.Patients who meet this exposure factor were included in the integrative medicine cohort(Group A),receiving conventional treatment combined with ST-CM;those who do not meet this exposure factor were included in the Western medicine cohort(Group B),receiving conventional treatment.The overall survival(OS)and survival rates from the lst,2nd,and 3rd year were compared between the two groups.Results A total of 519 patients were recruited in this study.The median overall survival(mOS)for cohort A(324 cases)and cohort B(195 cases)were 34.3 months and 21.3 months,respectively(HR 0.65,95%CI:0.535-0.793,P<0.001).The survival rates at 1 st,2nd and 3rd years for Group A and Group B were 95.6%and 83.2%,38.6%and 24.7%,21.6%and 12.4%,respectively,with group A showing better outcomes than group B(P<0.001).Subgroup analysis revealed that regardless of gender,primary tumor site,genetic type,combination with targeted therapy,presence of liver metastasis,and absence of peritoneal metastasis,Group A's mOS was significantly better than Group B,with all differences being statistically significant(P<0.05).Conclusion ST-CM combined with chemotherapy can prolong the OS of mCRC patients,and improve the survival rates from the 1st,2nd and 3rd year.
